Changes in human whole blood 5-hydroxytryptamine (5-HT) and platelet 5-HT uptake during treatment with paroxetine,a selective 5-HT uptake inhibitor

Abstract

The effects of the specific 5-hydroxytryptamine (5-HT) reuptake inhibitor parox etine on whole blood 5-HT and the uptake of ³H-5-HT by platelets was determined in 17 patients with resistant depression. The biochemical parameters were measured before paroxetine treatment, during treatment and after withdrawal of treatment. Two of the 17 subjects failed to complete the trial; of the remaining subjects 12 showed a marked decrease in whole blood 5-HT and ³H-5-HT uptake into platelets. The remaining three patients showed a variable response both in terms of whole blood 5-HT and platelet uptake during paroxetine treatment. At the end of treatment blood 5-HT tended to return towards normal although this was delayed. There was no significant correlation between the change in blood 5-HT and Hamilton score during paroxetine treatment. The results confirm that inhibition of 5-HT uptake mech anisms are associated with decreased whole blood 5-HT but that changes in whole blood 5- HT do not necessarily reflect the clinical efficacy of 5-HT uptake blocking drugs in the treatment of depression.

Get full access to this article

View all access options for this article.

References

Buss Lassen L. 1978

Influence of the new 5-HT-uptake inhibitor paroxetine on hypermotility in rats produced by p-chloroamphetamine (PCA) and 4 1-dimethyl-m-tyramine (H77/77)

Psychopharmacology 57 151-153

Ebbe S. 1971 Origin, production and life span of blood platelets In. The circulating platelet (ed S. A Johnson), pp 19-43 Academic Press, New York

Feighner J.P. Robins E. Guze S.B. Woodruff R.A. Winokur G. 1972 Diagnostic criteria for use in psychiatric research . Archives of General Psychiatry 26: 56-73

Gayford J.J. Parker A.L. Phillips E.M. Rowsell A.R. 1973

Whole blood 5-hydroxytryptamine during treatment of endogenous depressive illness

British Journal of Psychiatry 122: 597-598

Hamilton M. 1960

A rating scale for depression

Journal of Neutrology Neurosurgery and Psychiatry 23: 56-61

Lingjaerde O. Bratfos O. Bratlid T. Haug J.O. 1983

A double-blind comparison of 3 imelidine and desipramine in endogenous depression

Acta Psychiatrica Scandinavica 68: 22-30

Lund Laursen A. Mikkelsen P.L. Rasmussen S. Le Fevre Honore P. 1985 Paroxetme in the treatment of depression— a randomized comparison with amitriptyline. Acta Psychiatrica Scandinavica 71. 249-255

Lund J. Lomholt B. Fabricius J. Christensen J.A. Bechgaard E. 1979 Paroxetme. pharmacokinetics, tolerance and depletion of blood 5HT in man. Acta Pharmacologica Toxicologica 44: 289-295

Marsden C.A. Joseph M.H. 1986 Biogenic amines. In HPLC of small molecules, a practical approach (ed C K Lim), pp. 29-47. IRL Press, Oxford

10.

Marshall E.F. Stirling G.S. Tait A.C. Todrick A. 1960

The effect of iproniazid and imipramine on the blood platelet 5-hydroxytryptamine level in man

British Journal of Pharmacology 15: 35-41

11.

Petersen E.N. Bechgaard E. Sortwell R.J. Wetterberg L. 1978

Potent depletion of 5HT from monkey whole blood by a new 5HT uptake mhibitor, paroxetine (FG 7051)

European Journal of Pharmacology 52: 115-119

12.

Ross S.B. Aperia B. Beck-Frus J. Jansa S. Wetterberg L. Asberg A. 1980 Inhibition of 5-hydroxytryptamine uptake in human platelets by antidepressant agents in vivo. Psychopharmacology 67: 1-7

13.

Rudnick G. Fishkes H. Nelson P.J. Schuldmer S. 1980 Evidence for two distinct serotonin transport systems in platelets. Journal of Biological Chemistry 255: 3638-3641

14.

Somerville B.W. 1976

Platelet-bound and free serotonin levels in jugular and forearm venous blood during migrame

Neurology 26: 41-45

15.

Tyrer P. Marsden C.A. Casey P. Seivewright N. 1988 Clinical efficacy of paroxetine in resistant depression . Journal of Psychopharmacology 4